Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neurol Sci. 2014 Feb 15;337(1-2):18-24. doi: 10.1016/j.jns.2013.11.011. Epub 2013 Nov 16.

Long-term effects of dalfampridine in patients with multiple sclerosis.

Author information

1
Department of Neurology - University of Münster, Albert-Schweitzer-Campus 1, Building A 10, 48149 Münster, Germany.
2
Department of Neurology - University of Münster, Albert-Schweitzer-Campus 1, Building A 10, 48149 Münster, Germany. Electronic address: sven.meuth@ukmuenster.de.

Abstract

BACKGROUND/OBJECTIVE:

Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9-12 months.

METHODS:

Fifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2 weeks and after 9-12 months later.

RESULTS:

Thirty out of fifty-two patients (~60%) were still on treatment after 9-12 months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9-12 months. In contrast significant effects for velocity were observed only after 2 weeks, for improvement in PASAT only after 9-12 months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients.

CONCLUSION:

Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS.

KEYWORDS:

Dalfampridine; Fatigue; Long-term treatment; MS; Mobility; Walking ability

PMID:
24290498
DOI:
10.1016/j.jns.2013.11.011
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center